HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Substrate deprivation therapy in juvenile Sandhoff disease.

Abstract
Substrate deprivation therapy has been successfully applied in a number of lysosomal storage diseases, such as Gaucher disease. So far only limited experience is available in Sandhoff disease. We initiated substrate deprivation therapy in one male patient, who initially presented at the age of 3.5 years with epilepsy and regression in motor skills and speech development. Juvenile Sandhoff disease was diagnosed on the basis of a decreased hexosaminidase activity in leukocytes and a homozygous HEXB gene mutation. After the epilepsy was controlled, the clinical course remained stable for years, defined by a mild proximal myopathy and stable mental retardation. At 14 years of age the patient experienced a second episode with progressively worsening general condition with diminishing muscle power and progressive ataxia. Treatment was started with the N-alkylated imino sugar miglustat, inhibiting the glucosylceramide synthase, an essential enzyme for the synthesis of glycosphingolipids. Diarrhoea was treated with lactose restriction. We performed detailed biochemical investigations, motor and mental development analysis, brain imaging, organ function studies and quality of life score prior to and at different time points after start of the treatment. Two years after the initiation of therapy the patient has a stable neurological picture without further regression in his motor development, ataxia or intelligence. There is a subjective improvement in the fine motor skills and walking up the stairs but no change in the quality of life score. Under treatment with miglustat the clinical course in our patient with Sandhoff disease did not further deteriorate.
AuthorsS B Wortmann, D J Lefeber, G Dekomien, M A A P Willemsen, R A Wevers, E Morava
JournalJournal of inherited metabolic disease (J Inherit Metab Dis) Vol. 32 Suppl 1 Pg. S307-11 (Dec 2009) ISSN: 1573-2665 [Electronic] United States
PMID19898952 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Enzyme Inhibitors
  • 1-Deoxynojirimycin
  • miglustat
  • Glucosyltransferases
  • ceramide glucosyltransferase
  • Hexosaminidase B
Topics
  • 1-Deoxynojirimycin (analogs & derivatives, therapeutic use)
  • Adolescent
  • Child, Preschool
  • Disease Progression
  • Enzyme Inhibitors (therapeutic use)
  • Glucosyltransferases (antagonists & inhibitors)
  • Hexosaminidase B (genetics)
  • Humans
  • Male
  • Mutation
  • Sandhoff Disease (drug therapy, genetics, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: